Spinal Mincle activation — new innate-immune-receptor arm for H2/H3

One-paragraph summary

Primary mechanism paper introducing intrathecal Mincle (macrophage-inducible C-type lectin, gene symbol CLEC4E) activation as a novel rodent neuropathic-pain model that does NOT require peripheral nerve injury. Intrathecal injection of the Mincle ligand TDB (trehalose-6,6'-dibehenate) at 0.1-10 μg produces persistent mechanical allodynia (day 1 through day 28), with faster microglial + astrocyte activation than the conventional spinal nerve ligation (SNL) model. Comparable pain hypersensitivity to SNL but via a sterile innate-immune route. This identifies Mincle as a new candidate entity for the project's ontology and a new candidate arm of the central-sensitization mechanism — independent of mast cells (H2), autoantibodies (H1), and predictive coding (H3), but engaging glial activation via the C-type lectin family of innate-immune receptors.

Claims as triples

• mincle_clec4e — activated_by → trehalose_6_6_dibehenate_TDB [evidence: established receptor pharmacology; confidence: established]
• intrathecal_TDB — produces → persistent_mechanical_allodynia [evidence: primary behavioral, day 1-28; confidence: emerging — single study]
• intrathecal_TDB — produces → microglial_activation_iba1 [evidence: primary IHC; confidence: emerging]
• intrathecal_TDB — produces → astrocyte_activation_GFAP [evidence: primary IHC; confidence: emerging]
• mincle_activation — produces_pain → independent_of_peripheral_nerve_injury [evidence: primary; confidence: emerging — significant model design implication]
• repeated_intrathecal_TDB — comparable_pain_to → spinal_nerve_ligation [evidence: primary head-to-head; confidence: emerging]
• mincle_activation — faster_glial_response_than → spinal_nerve_ligation [evidence: primary head-to-head; confidence: emerging]

Methods note

Rodent intrathecal injection of Mincle ligand TDB at three single-injection doses (0.1, 1, 10 μg single bolus, S-TDB) and repeated injection (10 μg/day × 2 days, R-TDB). Head-to-head comparison with surgical spinal nerve ligation (SNL). Outcomes: mechanical/thermal pain testing days 1-28, spinal cord IHC for Iba1 (microglia) and GFAP (astrocytes). Comprehensive primary mechanism work.

Limitations

• Rodent model only
• No FM-direct demonstration
• Mincle's natural endogenous ligands in chronic pain settings not addressed (TDB is mycobacterial-derived; endogenous DAMPs that activate Mincle include cholesterol crystals, damaged self-molecules — these would be the chronic-pain-relevant activators)
• Single dose duration (28 days) — chronic > 28 day phase not tested
• No comparison with mast-cell-targeting interventions (so Mincle vs MC route distinction not yet tested in this model)
• Mechanism downstream of Mincle activation in this context not fully dissected — receptor → glial activation pathway not detailed beyond IHC

Open questions raised

• Q-Mincle-1 (new): Is Mincle (CLEC4E) expressed in FM patient peripheral immune cells or spinal glia? Tissue/biopsy/post-mortem assessment needed.
• Q-Mincle-2 (new): What endogenous DAMPs activate Mincle in chronic pain conditions? Cholesterol crystals (CRPS, atherosclerosis), SAP130 (necrotic cells), β-glucosylceramide are known ligands. FM mechanism would require identifying the FM-relevant endogenous activator.
• Q-Mincle-3 (new): Are Mincle inhibitors / Mincle-pathway-blockers in clinical development? (Currently scarce; one preclinical inhibitor is reported. Could be a new cure-path-arm candidate.)
• Q-Mincle-4 (new): Does Mincle activation intersect with the Sanchez 2025 MRGPRX2-MC pathway? Both are innate-immune-receptor activations in different cell types; cross-talk between MC (MRGPRX2) and microglia (Mincle) could amplify pain via shared cytokine outputs (IL-1β, TNF-α).

Triangulation notes

• Distinct from H1/H2/H3: doesn't fit autoimmune-IgG, mast-cell, or predictive-coding chains. Proposes a new arm — innate-immune-glial chain — that operates via C-type lectin receptors on microglia and astrocytes. Could be related to H4 (immuno-metabolic) if endogenous Mincle activators are lipid/sterol species elevated in metabolic syndrome.
• Compatible with the project's neuroinflammation_glial chain: doesn't introduce a new endpoint (microglial + astrocyte activation already in mechanism map) but supplies a new upstream activator.
• New candidate cure-path arm: Mincle pathway-targeting. Currently absent from cure-path-arm-decisions. Watchlist tier pending clinical-stage Mincle inhibitor development.
• Could intersect with the Mediator-of-Inflammation cascade: Mincle activation in microglia would release IL-1β, TNF-α — same cytokines as in MC degranulation. Downstream effects on dorsal-horn disinhibition (via the BDNF-chloride homeostasis route already in ontology) are likely shared.

Bridges

• B-Mincle (NEW candidate): Innate immune receptor (Mincle / C-type lectin family) activation ↔ FM neuroinflammation. Bridging tier — predicted by analogy to the H2 (MC) and H1 (IgG) chains' use of innate immune receptors on different cell types. The FM-direct demonstration is absent; would close by showing Mincle/CLEC4E upregulation in FM patient spinal tissue or by trial of a Mincle inhibitor in stratified FM.

Ontology additions needed

• Add mincle (CLEC4E) as new entity, type: receptor / innate-immune-receptor, confidence: bridging
• Add C-type lectin receptor family as type-category if not present
• Add mincle_inhibitor as candidate intervention class
• Add TDB (trehalose-6,6'-dibehenate) as research-tool molecule

Confidence-tier framing

• Mincle activation produces pain in rodent: established (within this primary study + cited Mincle-pain literature)
• Mincle as candidate arm in FM: inferred (mechanism analogy; no FM-direct evidence yet)
• Mincle as cure-path-arm target: bridging (no clinical-stage Mincle inhibitor for any indication yet; very early)